On Feb. 12, 2021, BD (Becton, Dickinson) announced that the FDA had granted Emergency Use Authorization (EUA) for a new molecular diagnostic test for both SARS-CoV-2 and Influenza A+B that can return results in two to three hours. The new test also had been CE marked to the IVD Directive (98/79/EC).